Ground-breaking work by university experts in Tennessee, Texas and Swansea University is helping develop a better understanding of the growing threat posed by antifungal drug resistance.
Invasive aspergillosis is a devastating disease caused by breathing in small airborne spores of the fungus Aspergillus fumigatus and it is a condition where drug resistance has been encountered.
In a healthy person these spores are destroyed by the body's immune system but in those with a weakened immune system -- such as following organ transplantation or in someone with a lung condition such as asthma or cystic fibrosis -- they can trigger a range of problems including infections.
Every year aspergillosis leads to more than 200,000 life-threatening infections and increasingly resistance to vital antifungal drug treatments makes those infections harder to treat.
National Institutes of Health funding supported a collaboration between the University of Tennessee, the University of Texas and Swansea University as part of a $2 million, five-year research program. This support enabled investigation of resistance to the triazole class of antifungal drugs used for treating the disease
A new paper, published in the American Microbiology Society journal mBio, reveals how researchers have been able to identify a previously uncharacterised genetic mutation in clinical isolates that leads to resistance.
Professor Jarrod Fortwendel, from the University of Tennessee, said, "As with bacteria, antifungal drug resistance is a real challenge facing medicine. Understanding how the fungus becomes drug resistant is important for designing changes in therapy to overcome aspergillosis."
Professor Dave Rogers, also from the University of Tennessee, added, "It is very important that the research continues and we find out more about why it is happening and how we can tackle it for the future."
Swansea University's professor Steve Kelly, whose experience researching the field of antifungal resistance dates back to 1984, described the findings as a real breakthrough. "This paper is the result of a lot of hard work and we are delighted to now be able to publish our findings."
Source: Swansea University
Ensuring Safe Practices: Managing Surgical Instruments in the Context of Creutzfeldt-Jakob Disease
February 27th 2025Creutzfeldt-Jakob Disease (CJD) presents significant challenges for infection control. Learn best practices for safe instrument disposal, reprocessing, and compliance with CDC and WHO guidelines.
Confronting Superbugs: The Critical Battle Against Antimicrobial Resistance
February 25th 2025Antimicrobial resistance (AMR) increasingly challenges medicine advancements. Limited diagnostics delay treatment, causing higher hospitalizations and mortality. Antibiotic overuse in low-income countries worsens resistance. Pharmaceutical companies must invest in research and global stewardship to mitigate AMR's effects.
Resilience and Innovation: The Pivotal Contributions of Black Americans to Health Care and Medicine
February 24th 2025During Black History Month, we honor the resilience and contributions of Black medical professionals in health care. Despite barriers, they have led transformative changes, advocating for equitable access and medical excellence. Recognizing their impact ensures a more inclusive health care future for all.